See more : Pacific Energy & Mining Company (PEMC) Income Statement Analysis – Financial Results
Complete financial analysis of Tempest Therapeutics, Inc. (TPST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tempest Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Luduson G Inc. (LDSN) Income Statement Analysis – Financial Results
- Korea Investment Holdings Co., Ltd. (071050.KS) Income Statement Analysis – Financial Results
- ARIAKE JAPAN Co., Ltd. (AKEJF) Income Statement Analysis – Financial Results
- United States Cellular Corporation CALL SR NT 60 (UZA) Income Statement Analysis – Financial Results
- Arqit Quantum Inc. (ARQQ) Income Statement Analysis – Financial Results
Tempest Therapeutics, Inc. (TPST)
About Tempest Therapeutics, Inc.
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 295.00K | 653.00K | 277.00K | 9.74M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 381.00K | 1.81M | 1.27M | 815.00K | 1.05M | 32.00K | 28.00K | 5.40M | 2.25M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -381.00K | -1.81M | -1.27M | -815.00K | -1.05M | -32.00K | 267.00K | -4.75M | -1.97M | 9.74M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 90.51% | -727.11% | -711.91% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 17.50M | 22.53M | 17.17M | 14.39M | 27.84M | 14.43M | 14.53M | 21.64M | 18.43M | 21.78M | 15.80M | 6.32M | 1.17M |
| General & Administrative | 11.66M | 12.11M | 9.82M | 4.91M | 5.51M | 12.45M | 27.74M | 49.22M | 51.59M | 26.15M | 13.33M | 7.21M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 16.50M | -3.79M | -21.82M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.66M | 12.11M | 9.82M | 4.91M | 16.50M | 8.66M | 5.93M | 49.22M | 51.59M | 26.15M | 13.33M | 7.21M | 1.45M |
| Other Expenses | 0.00 | 549.00K | -34.00K | 0.00 | 0.00 | 0.00 | 4.03M | 5.40M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 29.16M | 34.64M | 26.99M | 19.30M | 44.35M | 23.08M | 20.45M | 70.86M | 70.03M | 47.93M | 29.13M | 13.53M | 2.62M |
| Cost & Expenses | 29.16M | 34.64M | 26.99M | 19.30M | 45.40M | 23.12M | 20.48M | 76.27M | 72.28M | 47.93M | 29.13M | 13.53M | 2.62M |
| Interest Income | 1.12M | 549.00K | 1.28K | 90.00K | 264.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 19.00K | 0.00 |
| Interest Expense | 1.45M | 1.62M | 1.28M | 0.00 | 0.00 | 134.00K | 0.00 | 659.00K | 436.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 381.00K | 1.81M | 1.27M | 815.00K | 1.05M | 32.00K | 28.00K | 2.24M | 1.29M | 450.00K | 231.00K | 0.00 | 0.00 |
| EBITDA | -28.78M | -32.28M | -25.72M | -18.39M | -43.52M | -27.01M | -84.27M | -79.82M | -71.86M | -49.07M | -28.81M | -13.53M | -2.62M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -6,933.56% | -11,236.45% | -25,528.16% | -504.06% | 0.00% | 0.00% | 0.00% |
| Operating Income | -29.16M | -34.64M | -26.99M | -19.30M | -45.40M | -23.12M | -20.48M | -75.61M | -72.00M | -47.93M | -29.13M | -13.53M | -2.62M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -6,943.05% | -11,579.17% | -25,992.42% | -492.38% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -334.00K | -1.07M | -1.32M | 90.00K | -21.19M | -4.06M | -64.10M | -1.05M | -1.15M | -1.59M | 90.00K | 19.00K | 0.00 |
| Income Before Tax | -29.49M | -35.71M | -28.30M | -19.21M | -44.57M | -27.18M | -84.59M | -82.06M | -73.14M | -49.52M | -29.04M | -13.51M | -2.62M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -28,673.22% | -12,566.46% | -26,405.78% | -508.68% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 1.07M | 1.25M | -90.00K | 1.00K | -169.00K | 67.00K | 201.00K | 75.00K | -1.59M | 90.00K | 0.00 | 0.00 |
| Net Income | -29.49M | -36.78M | -29.55M | -19.12M | -44.57M | -27.19M | -84.58M | -82.26M | -73.22M | -49.52M | -29.04M | -13.51M | -2.73M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -28,670.51% | -12,597.24% | -26,432.85% | -508.68% | 0.00% | 0.00% | 0.00% |
| EPS | -1.91 | -3.18 | -7.80 | -612.56 | -48.77 | -263.65 | -72.41K | -575.73 | -608.25 | -491.98 | -288.55 | -2.33 | 0.00 |
| EPS Diluted | -1.91 | -3.18 | -7.80 | -612.56 | -48.77 | -263.65 | -72.41K | -575.73 | -608.25 | -491.98 | -288.55 | -2.33 | 0.00 |
| Weighted Avg Shares Out | 15.42M | 11.55M | 3.79M | 31.21K | 913.78K | 103.14K | 1.17K | 142.88K | 120.38K | 100.65K | 100.65K | 0.00 | 0.00 |
| Weighted Avg Shares Out (Dil) | 15.42M | 11.55M | 3.79M | 31.21K | 913.78K | 103.14K | 1.17K | 142.88K | 120.38K | 100.65K | 100.65K | 0.00 | 0.00 |
Tempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting
BRISBANE, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that two abstracts have been accepted for poster presentation at the...
Tempest to Present at the Piper Sandler 34th Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company focused on developing first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced that management will participate in a fireside...
Tempest to Present at Emerging Technologies for IO Targeting and Discovery Summit
SOUTH SAN FRANCISCO, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that Dara Burdette, Ph.D., Senior Director of Discovery Research...
Tempest to Present at the Jefferies Healthcare Conference
SOUTH SAN FRANCISCO, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that management will present at the Jefferies Healthcare Conference...
3 Must Watch Penny Stocks For Your Small-Caps List
These must watch penny stocks are worth giving a look The post 3 Must Watch Penny Stocks For Your Small-Caps List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Why Tempest Therapeutics Shares Are Rising
Tempest Therapeutics Inc (NASDAQ: TPST) shares are trading higher by 29.24% at $3.05 after the company announced $15 million of private placement financing. The $15 million private investment in public equity (PIPE) financing comes from the sale of 3,149,912 shares...
Tempest to Present at the 32nd Annual Oppenheimer Healthcare Conference
SOUTH SAN FRANCISCO, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that management will present at the 32nd Annual Oppenheimer...
Tempest to Present Two Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting
SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced two poster presentations at the 2022 American Association for...
H.C. Wainwright Says Targeted Oncology Therapies "Gives An Edge" To Tempest Therapeutics
H.C. Wainwright has initiated coverage of Tempest Therapeutics Inc (NASDAQ: TPST) with a Buy rating and $51 price target, seeing an upside potential of over 100%. A strategic portfolio of targeted therapies in oncology "gives Tempest an edge," analyst Joseph Pantginis tells investors in...
What's Going On With Tempest Therapeutics Stock?
Shares of the South San Francisco-based micro-cap biopharma Tempest Therapeutics Inc. (NASDAQ: TPST) were soaring Monday for a second consecutive trading session on above-average volume. Tempest's Wild Ride: Tempest, which recently began trading on the Nasdaq through a reverse merger with Millendo...
Source: https://incomestatements.info
Category: Stock Reports